"Take a Statin and Call Me in the Morning"- Are Statins the New Aspirin?

Pharmacy Times
Volume 75
Issue 12

As we hear about the many wonders of statin therapy-most recently blood pressure reduction-it recalls the past 30 years of debate about the benefits of daily aspirin.

Joanne LaFleur is an assistant professor in the department of pharmacotherapy at the University of Utah College of Pharmacy.

When Heart Protection Study researchers unveiled their findings at the American Heart Association meeting in 2001, in their enthusiasm for the mortality benefits they found, they declared statins to be the new aspirin.1 Since then, the years have brought us frequent reports in the scientific literature about the many beneficial pleiotropic (nonlipid) effects of statin therapy (Table2-61). As we hear about these many wonders of statin therapy—most recently blood pressure reduction—it recalls to mind the past 30 years of debate about the benefits of daily aspirin for preventing everything from cardiovascular disease to cancer, and even dementia.62

Although the benefits of aspirin therapy are well-documented, particularly for cardiovascular disease prevention, we also now know that the risks of daily aspirin therapy may outweigh the benefits in several important subsets of the population.63 That is why we should carefully consider the evidence showing beneficial pleiotropic effects of the statin class before we similarly begin to regard it as a panacea. As a case in point, let us consider the evidence of the statin’s effects on blood pressure, which was the subject of a recent clinical trial.64

Statin Effects on Blood Pressure

Between 1999 and 2005, many observational studies showed small blood pressure reductions in hypertensive patients who were receiving statins.39-43 Some small-scale randomized controlled trials also studied blood pressure changes in statin recipients, but many showed conflicting results.44-47 Following these reports, clinicians and researchers remained uncertain about the effect of statins on blood pressure. The observational studies were conducted in widely differing patient populations, among whom numerous confounders were present; most of the randomized controlled trials were not designed to evaluate blood pressure as a primary end point; and above all, the effect sizes were very small.

Better data were soon forthcoming. A meta-analysis, published last year, concluded, on the basis of data from 563 patients from more than 20 randomized controlled trials, that statins reduced systolic blood pressure an average of 1.9 mm Hg.48 That was rather an underwhelming effect size, but the reduction was a little bit greater—4.0 mm Hg—in the subset of patients with baseline systolic blood pressure >130 mm Hg. Researchers found no effect on diastolic blood pressure. Following that analysis, the largest randomized controlled clinical trial to date (which included more patients than all the studies in the meta-analysis combined) showed in 973 men and women that statins reduced systolic blood pressure by 2.2 mm Hg and diastolic blood pressure by 2.4 mm Hg.64

Could the effects reported by these researchers be a result of chance or error? After all, an effect size of 2 mm Hg could easily be attributable to measurement error. Measurement error would not be a plausible explanation, however, unless we thought systematic differences existed in the blood pressure measurement methods between patients who received statins compared with those who did not. And, although random chance cannot be completely ruled out, it is an unlikely explanation. The statistics reported in these studies tell us that the likelihood that findings were due to random chance was less than 1 in 100 for the meta-analysis and less than 1 in 1000 for the clinical trial. These probabilities are well below established thresholds for determining “statistical” significance.


The impact of statins on blood pressure may be a real effect, but undoubtedly, the effect size is small—so small, in fact, that it may be safely disregarded. Findings from the recent clinical trial and meta-analysis suggest that any blood pressure effect of statins is certainly lower than the average effect of antihypertensive drugs. Therefore, statins should continue to be used for patients with dyslipidemias, particularly low-density lipoprotein elevations, and in patients with established coronary artery disease or risk equivalents (such as diabetes). Statins should not be considered as a means of reducing blood pressure. â– 



Kmietowicz Z. Statins are the new aspirin, Oxford researchers say. BMJ. 2001;323(7322):1145.


Fauchier L, Pierre B, de Labriolle A, Grimard C, Zannad N, Babuty D. Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2008;51(8):828-835.


Liu T, Li L, Korantzopoulos P, Liu E, Li G. Statin use and development of atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials and observational studies. Int J Cardiol. 2008;126(2):160-170.


Patti G, Chello M, Candura D, et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation. 2006;114(14):1455-1461.


Friis S, Poulsen AH, Johnsen SP, et al. Cancer risk among statin users: a population-based cohort study. Int J Cancer. 2005;114(4):643-647.


Karp I, Behlouli H, Lelorier J, Pilote L. Statins and cancer risk. Am J Med. 2008;121(4):302-309.


Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ. The risk of cancer in users of statins. J Clin Oncol. 2004;22(12):2388-2394.


Poynter JN, Gruber SB, Higgins PD, et al. Statins and the risk of colorectal cancer. N Engl J Med. 2005;352(21):2184-2192.


Khurana V, Bejjanki HR, Caldito G, Owens MW. Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans. Chest. 2007;131(5):1282-1288.


Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE. Serum lipids, lipid-lowering drugs, and the risk of breast cancer. Arch Intern Med. 2005;165(19):2264-2271.


Kaye JA, Jick H. Statin use and cancer risk in the General Practice Research Database. Br J Cancer. 2004;90(3):635-637.


Jacobs EJ, Rodriguez C, Brady KA, Connell CJ, Thun MJ, Calle EE. Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort. J Natl Cancer Inst. 2006;98(1):69-72.


Coogan PF, Smith J, Rosenberg L. Statin use and risk of colorectal cancer. J Natl Cancer Inst. 2007;99(1):32-40.


Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol. 2005;23(34):8606-8612.


Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-1278.


Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a meta-analysis. JAMA. 2006;295(1):74-80.


Browning DR, Martin RM. Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer. 2007;120(4):833-843.


Tonelli M, Moye L, Sacks FM, Cole T, Curhan GC. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol. 2003;14(6):1605-1613.


Vidt DG, Cressman MD, Harris S, Pears JS, Hutchinson HG. Rosuvastatin-induced arrest in progression of renal disease. Cardiology. 2004;102(1):52-60.


Vega GL, Weiner MF, Lipton AM, et al. Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease. Arch Neurol. 2003;60(4):510-515.


Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000;57(10):1439-1443.


Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet. 2000;356(9242):1627-1631.


Rodriguez EG, Dodge HH, Birzescu MA, Stoehr GP, Ganguli M. Use of lipid-lowering drugs in older adults with and without dementia: a community-based epidemiological study. J Am Geriatr Soc. 2002;50(11):1852-1856.


Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry. 2009;80(1):13-17.


Li G, Higdon R, Kukull WA, et al. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology. 2004;63(9):1624-1628.


Rea TD, Breitner JC, Psaty BM, et al. Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch Neurol. 2005;62(7):1047-1051.


Dufouil C, Richard F, Fievet N, et al. APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study. Neurology. 2005;64(9):1531-1538.


Bernick C, Katz R, Smith NL, et al. Statins and cognitive function in the elderly: the Cardiovascular Health Study. Neurology. 2005;65(9):1388-1394.


Masse I, Bordet R, Deplanque D, et al. Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2005;76(12):1624-1629.


Li G, Larson EB, Sonnen JA, et al. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology. 2007;69(9):878-885.


Szwast SJ, Hendrie HC, Lane KA, et al. Association of statin use with cognitive decline in elderly African Americans. Neurology. 2007;69(19):1873-1880.


Arvanitakis Z, Schneider JA, Wilson RS, et al. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology. 2008;70(19 Pt 2):1795-1802.


Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001;103(3):357-362.


Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207.


Vaughan CJ, Gotto AM Jr, Basson CT. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol. 2000;35(1):1-10.


Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation. 2000;101(2):207-213.


Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357(22):2248-2261.


Borghi C, Prandin MG, Costa FV, Bacchelli S, Degli Esposti D, Ambrosioni E. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol. 2000;35(4):549-555.


Prasad GV, Ahmed A, Nash MM, Zaltzman JS. Blood pressure reduction with HMG-CoA reductase inhibitors in renal transplant recipients. Kidney Int. 2003;63(1):360-364.


Sposito AC, Mansur AP, Coelho OR, Nicolau JC, Ramires JA. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol. 1999;83(10):1497-1499, A1498.


Kanbay M, Yildirir A, Bozbas H, et al. Statin therapy helps to control blood pressure levels in hypertensive dyslipidemic patients. Ren Fail. 2005;27(3):297-303.


Leibovitz E, Hazanov N, Zimlichman R, Shargorodsky M, Gavish D. Treatment with atorvastatin improves small artery compliance in patients with severe hypercholesterolemia. Am J Hypertens. 2001;14(11 Pt 1):1096-1098.


Terzoli L, Mircoli L, Raco R, Ferrari AU. Lowering of elevated ambulatory blood pressure by HMG-CoA reductase inhibitors. J Cardiovasc Pharmacol. 2005;46(3):310-315.


O'Callaghan CJ, Krum H, Conway EL, et al. Short term effects of pravastatin on blood pressure in hypercholesterolaemic hypertensive patients. Blood Press. 1994;3(6):404-406.


Derosa G, Mugellini A, Ciccarelli L, Fogari R. Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. Clin Ther. 2003;25(4):1107-1122.


Glorioso N, Troffa C, Filigheddu F, et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension. 1999;34(6):1281-1286.


Ferrier KE, Muhlmann MH, Baguet JP, et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol. 2002;39(6):1020-1025.


Strazzullo P, Kerry SM, Barbato A, Versiero M, D'Elia L, Cappuccio FP. Do statins reduce blood pressure?: a meta-analysis of randomized, controlled trials. Hypertension. 2007;49(4):792-798.


LaCroix AZ, Cauley JA, Pettinger M, et al. Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women's Health Initiative Observational Study. Ann Intern Med. 2003;139(2):97-104.


Bauer DC, Mundy GR, Jamal SA, et al. Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med. 2004;164(2):146-152.


Reid IR, Hague W, Emberson J, et al. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. Lancet. 2001;357(9255):509-512.


Pedersen TR, Kjekshus J. Statin drugs and the risk of fracture. 4S Study Group. JAMA. 2000;284(15):1921-1922.


Nagashima T, Okazaki H, Yudoh K, Matsuno H, Minota S. Apoptosis of rheumatoid synovial cells by statins through the blocking of protein geranylgeranylation: a potential therapeutic approach to rheumatoid arthritis. Arthritis Rheum. 2006;54(2):579-586.


Leung BP, Sattar N, Crilly A, et al. A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol. 2003;170(3):1524-1530.


Yamagata T, Kinoshita K, Nozaki Y, Sugiyama M, Ikoma S, Funauchi M. Effects of pravastatin in murine collagen-induced arthritis. Rheumatol Int. 2007;27(7):631-639.


Stefanec T. The effects of statins on mortality rates among bacteremic patients. Clin Infect Dis. 2002;34(8):1158.


Almog Y, Shefer A, Novack V, et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation. 2004;110(7):880-885.


Thomsen RW, Hundborg HH, Johnsen SP, et al. Statin use and mortality within 180 days after bacteremia: a population-based cohort study. Crit Care Med. 2006;34(4):1080-1086.


Hackam DG, Mamdani M, Li P, Redelmeier DA. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet. 2006;367(9508):413-418.


Gupta R, Plantinga LC, Fink NE, et al. Statin use and sepsis events [corrected] in patients with chronic kidney disease. JAMA. 2007;297(13):1455-1464.


Majumdar SR, McAlister FA, Eurich DT, Padwal RS, Marrie TJ. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ. 2006;333(7576):999.


Iredale RT. Citizen jury should consider aspirin prophylaxis. BMJ. 2005;331(7509):160.


Nelson MR, Liew D, Bertram M, Vos T. Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged > or =70. BMJ. 2005;330(7503):1306.


Golomb BA, Dimsdale JE, White HL, Ritchie JB, Criqui MH. Reduction in blood pressure with statins: results from the UCSD Statin Study, a randomized trial. Arch Intern Med. 2008;168(7):721-727.

Related Videos
Practice Pearl #1 Active Surveillance vs Treatment in Patients with NETs
© 2024 MJH Life Sciences

All rights reserved.